Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

NCT05590221 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma

Interventions

BIOLOGICAL: Relmacabtagene Autoleucel
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Peking University Cancer Hospital & Institute

Collaborators

[object Object]